The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study

Journal of Psychopharmacology

Volumn 28, Issue 7, 2014, Pages 633-642

  Machielsen, Marise W J ^a   Veltman, Dick J ^b   Van Den Brink, Wim ^a   De Haan, Lieuwe ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

addictive behaviour; antipsychotic agents; Cannabis; clozapine; functional magnetic resonance imaging; risperidone; schizophrenia

Indexed keywords

BIPERIDEN; CLOZAPINE; OXAZEPAM; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; ATTENTIONAL BIAS; BRAIN REGION; CANNABIS ADDICTION; CANNABIS USE DISORDER; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INSULA; MAJOR CLINICAL STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; STROOP TEST; TREATMENT DURATION; WELLBEING; WITHDRAWAL SYNDROME; ADOLESCENT; BRAIN MAPPING; COMPARATIVE STUDY; CRAVING; DIAGNOSTIC IMAGING; DRUG EFFECTS; MALE; NETHERLANDS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ATTENTIONAL BIAS; BRAIN MAPPING; CLOZAPINE; CRAVING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MARIJUANA ABUSE; NETHERLANDS; PREDICTIVE VALUE OF TESTS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STROOP TEST; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902573298     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114527357     Document Type: Article

References (56)

1. Bassett D, Bullmore ET, Meyer-Lindenberg A, et al. Cognitive fitness of cost-efficient brain functional networks. Proc Natl Acad Sci U S A. 2009 ; 106: 11747-11752
2. Bush G, Whalen PJ, Shin LM, et al. The counting Stroop: A cognitive interference task. Nat Protoc. 2006 ; 1: 230-233
3. Bush G, Whalen PJ, Rosen BR, et al. The counting Stroop: An interference task specialized for functional neuroimaging - validation study with functional MRI. Hum Brain Mapp. 1998 ; 6: 270-282
4. Carpenter KM, Schreiber E, Church S, et al. Drug Stroop performance: Relationships with primary substance of use and treatment outcome in a drug-dependent outpatient sample. Addict Behav. 2006 ; 31: 174-181
5. Cox WM, Fadardi JS, Pothos EM. The addiction-Stroop test: Theoretical considerations and procedural recommendations. Psychol Bull. 2006 ; 132: 443-476
6. De Haan L, Weisfelt M, Dingemans P, et al. Psychometric properties of the subjective well-being under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology (Berl). 2002 ; 162: 24-28
7. de Haan L, Booij J, Lavalaye J, et al. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. Psychopharmacology (Berl). 2006 ; 183: 500-505
8. Dekker N, Koeter M, Van Den Brink W, et al. Craving for cannabis in patients with psychotic disorder, their non-affected siblings and healthy controls: Psychometric analysis of the obsessive compulsive drug use scale. Int J Methods Psychiatr Res. 2012 ; 21: 286-300
9. Dixon L. Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophr Res. 1999 ; 35: S93 - S100
10. Ersche KD, Bullmore ET, Craig KJ, et al. Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence. Arch Gen Psychiatry. 2010 ; 67: 632
11. Field M, Cox WM. Attentional bias in addictive behaviors: A review of its development, causes, and consequences. Drug Alcohol Depend. 2008 ; 97: 1-20
12. Field M, Munafo MR, Franken IH. A meta-analytic investigation of the relationship between attentional bias and subjective craving in substance abuse. Psychol Bull. 2009 ; 135: 589-607
13. Franken IH. Drug craving and addiction: integrating psychological and neuropsychopharmacological approaches. Prog Neuropsychopharmacol Biol Psychiatry. 2003 ; 27: 563-579
14. Franken IH, Hendriks VM, Stam CJ, et al. A role for dopamine in the processing of drug cues in heroin dependent patients. Eur Neuropsychopharmacol. 2004 ; 14: 503-508
15. Franken IH, Stam CJ, Hendriks VM, et al. Neurophysiological evidence for abnormal cognitive processing of drug cues in heroin dependence. Psychopharmacology (Berl). 2003 ; 170: 205-212
16. Friston KJ, Holmes A, Poline JB, et al. Detecting activations in PET and fMRI: Levels of inference and power. Neuroimage. 1996 ; 4: 223-235
17. Goldstein RZ, Alia-Klein N, Tomasi D, et al. Anterior cingulate cortex hypoactivations to an emotionally salient task in cocaine addiction. Proc Natl Acad Sci U S A. 2009a ; 106: 9453-9458
18. Goldstein RZ, Tomasi D, Alia-Klein N, et al. Dopaminergic response to drug words in cocaine addiction. J Neurosci. 2009b ; 29: 6001-6006
19. Goldstein RZ, Tomasi D, Rajaram S, et al. Role of the anterior cingulate and medial orbitofrontal cortex in processing drug cues in cocaine addiction. Neuroscience. 2007 ; 144: 1153-1159
20. Green AI, Noordsy DL, Brunette MF, et al. Substance abuse and schizophrenia: Pharmacotherapeutic intervention. J Subst Abuse Treat. 2008 ; 34: 61-71
21. Heishman SJ, Evans RJ, Singleton EG, et al. Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend. 2009 ; 102: 35-40
22. Hester R, Garavan H. Neural mechanisms underlying drug-related cue distraction in active cocaine users. Pharmacol Biochem Behav. 2009 ; 93: 270-277
23. Janes AC, Pizzagalli DA, Richardt S, et al. Neural substrates of attentional bias for smoking-related cues: An FMRI study. Neuropsychopharmacology. 2010 ; 35: 2339-2345
24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987 ; 13: 261-276
25. Knowles EE, David AS, Reichenberg A. Processing speed deficits in schizophrenia: Reexamining the evidence. Am J Psychiatry. 2010 ; 167: 828-835
26. Kuhn S, Gallinat J. Common biology of craving across legal and illegal drugs - a quantitative meta-analysis of cue-reactivity brain response. Eur J Neurosci. 2011 ; 33: 1318-1326
27. Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: A validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008 ; 172: 199-212
28. Li W, van Tol M, Li M, et al. Regional specificity of sex effects on subcortical volumes across the lifespan in healthy aging. Hum Brain Mapp. 2014 ; 35: 238-247
29. Linszen DH, Dingemans PM, Lenior M E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994 ; 51: 273-279
30. Luijten M, Van Meel CS, Franken IHA. Diminished error processing in smokers during smoking cue exposure. Pharmacol Biochem Behav. 2011a ; 97: 514-520
31. Luijten M, Veltman DJ, Hester R, et al. Brain activation associated with attentional bias in smokers is modulated by a dopamine antagonist. Neuropsychopharmacology. 2012 ; 37: 2772-2779
32. Luijten M, Veltman DJ, van den Brink W, et al. Neurobiological substrate of smoking-related attentional bias. Neuroimage. 2011b ; 54: 2374-2381
33. Machielsen M, van der Sluis S, de Haan L. Cannabis use in patients with a first psychotic episode and subjects at ultra high risk of psychosis: impact on psychotic- and pre-psychotic symptoms. Aust N Z J Psychiatry. 2010 ; 44: 721-728
34. Machielsen MW, de Haan L. Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission. Psychopharmacol Bull. 2009 ; 42: 40-52
35. Marissen MA, Franken IH, Waters AJ, et al. Attentional bias predicts heroin relapse following treatment. Addiction. 2006 ; 101: 1306-1312
36. Minzenberg MJ, Laird AR, Thelen S, et al. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry. 2009 ; 66: 811-822
37. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995 ; 10: 133-138
38. Nestor L, McCabe E, Jones J, et al. Differences in "bottom-up" and "top-down" neural activity in current and former cigarette smokers: Evidence for neural substrates which may promote nicotine abstinence through increased cognitive control. Neuroimage. 2011 ; 56: 2258-2275
39. Nielsen MO, Rostrup E, Wulff S, et al. Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry. 2012 ; 69: 1195-1204
40. Perlstein WM, Carter CS, Noll DC, et al. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry. 2001 ; 158: 1105-1113
41. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990 ; 264: 2511-2518
42. Robins LN, Wing J, Wittchen HU, et al. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry. 1988 ; 45: 1069-1077
43. Robinson TE, Berridge KC. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993 ; 18: 247-291
44. Roesch-Ely D, Scheffel H, Weiland S, et al. Differential dopaminergic modulation of executive control in healthy subjects. Psychopharmacology (Berl). 2005 ; 178: 420-430
45. Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry. 2002 ; 47: 27-38
46. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935 ; 18: 643-6620
47. Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: Differentiation from other atypical antipsychotics. Am J Psychiatry. 2004 ; 161: 1620-1625
48. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002 ; 15: 273-289
49. Verheul R, van den Brink W, Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol. 1999 ; 34: 197-222
50. Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug abuse and addiction: Results of imaging studies and treatment implications. Arch Neurol. 2007 ; 64: 1575-1579
51. Vollstadt-Klein S, Loeber S, Richter A, et al. Validating incentive salience with functional magnetic resonance imaging: Association between mesolimbic cue reactivity and attentional bias in alcohol-dependent patients. Addict Biol. 2012 ; 17: 807-816
52. Voruganti LN, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia - findings from an in vivo SPECT study. Schizophr Res. 2006 ; 88: 179-186
53. Waters AJ, Shiffman S, Bradley BP, et al. Attentional shifts to smoking cues in smokers. Addiction. 2003 ; 98: 1409-1417
54. Wilkinson D, Halligan P. The relevance of behavioural measures for functional-imaging studies of cognition. Nat Rev Neurosci. 2004 ; 5: 67-73
55. Wobrock T, Falkai P, Schneider-Axmann T, et al. Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study. Schizophr Res. 2013 ; 147: 132-139
56. Worsley KJ, Marrett S, Neelin P, et al. A unified statistical approach for determining significant signals in images of cerebral activation. Hum Brain Mapp. 1996 ; 4: 58-73